FDA Rejects Capricor's Duchenne Cell Therapy

Regulators declined to approve deramiocel, a cell therapy aimed at teenagers and young men with Duchenne muscular dystrophy.

Updated on Nov. 21, 2026 in Biotech

Clear cell culture flasks of pale amber liquid sit on a steel laboratory bench in cool daylight, suggesting the lab work behind a rejected Duchenne therapy.
Capricor Therapeutics' cell therapy deramiocel was rejected by the U.S. Food and Drug Administration, blocking its path to market for Duchenne muscular dystrophy patients. AI Illustration. Upload story photo >

Live Poll

Do you trust the FDA to balance speed and safety for rare-disease treatments?

The U.S. Food and Drug Administration rejected deramiocel, a cell therapy developed by Capricor Therapeutics for Duchenne muscular dystrophy, in an announcement made on a Friday. The decision blocks the drug from reaching the market.

Why it matters

Duchenne is a progressive, muscle-wasting disease, and patients who have already lost the ability to walk have limited treatment options. The rejection leaves families and the company without an approved therapy for this group in the United States.

Two randomized clinical trials conducted by Capricor both failed to show deramiocel could stave off heart failure or preserve arm muscle function. The stub does not detail the trial sample sizes or whether the company plans to pursue further study.

The players

Capricor Therapeutics

Capricor Therapeutics is a clinical-stage biotechnology company developing cell-based therapies for cardiac and neuromuscular diseases.

U.S. Food and Drug Administration

The U.S. Food and Drug Administration is the federal agency responsible for approving drugs and biologics sold in the United States.

The details

The FDA rejected deramiocel from reaching the market after reviewing Capricor's clinical evidence. The company had tested the therapy in two randomized trials, and neither showed the drug could delay heart failure or protect arm muscle function in patients.

Timeline

  1. November 20, 2026: FDA announces rejection of deramiocel for Duchenne muscular dystrophy.

The Big Picture

The rejection tests how the FDA's rare-disease approval pathways apply to cell therapies whose trials did not meet their efficacy endpoints. It shows that unmet need alone does not overcome randomized trial results that fail to demonstrate benefit.

Families of boys and young men with Duchenne are left without an FDA-approved cell therapy option for now. Any future access will depend on whether Capricor pursues a resubmission or additional studies.

The takeaway

Regulatory rejection after failed randomized trials shows that promising mechanisms still require clear clinical benefit before reaching patients. Readers following rare-disease treatments should watch for any updated trial plans from Capricor.

Further reading

For more on drug development, see Biotech coverage across the United States.

Source note: This article includes information reported by STAT.

Live Poll

Do you trust the FDA to balance speed and safety for rare-disease treatments?